Omini and the EIC Accelerator: A Glucose Meter for Heart Failure

Omini, a French company registered in 2018 whose EIC project is based in Loos, near Lille, develops a handheld reader and disposable strips printed with organic electrochemical transistor sensors that can measure proteins, ions and metabolites together from a single drop of blood. Its EIC Accelerator project, CardioCap, "the first heart failure therapy management point-of-care device with multiplex and multimodal sensor", receives an EU contribution of €2,499,999 and runs from January 2025 to December 2026, according to CORDIS. It aims to let nurses and community clinics monitor heart failure patients' cardiac, kidney and electrolyte markers in under ten minutes, "to replicate, for complex chronic diseases, the impact that glucose meters had on diabetes management".

In the first year, the report says, Omini froze the design of its four-marker strip, standardised strip fabrication, and built and validated several reader prototypes "now ready for use in clinical studies", according to CORDIS. A retrospective clinical validation on human plasma from blood banks met target measurement ranges and precision for all four biomarkers against standard laboratory methods. Omini implemented quality processes aligned with the ISO 13485 medical device standard and passed a mock audit.

Where Omini Stands Now

Omini's website describes the platform as "in development". The official gazette BODACC records five capital increases between November 2024 and December 2025 and, in July 2026, changes to the board and a transfer of the registered office, according to BODACC. The amounts raised and the investors have not been announced, and its accounts are not in the public INPI dataset. No EIC Fund investment has been announced.

The Technology: Printed Transistors That Read Blood

Heart failure care depends on blood markers of cardiac function, kidney function and electrolyte balance, which today mostly need hospital-based testing, the EIC report says, so community teams adjust drugs with little data. Omini's organic transistors can be tuned to different molecules on the same printed strip. Screen printing keeps the cost per strip low, which the company says makes multiplex testing as affordable as single-marker tests.

What the EIC Award Promised, and What the Record Shows

The project runs to December 2026 and aims to prepare the device for regulatory approval. The first year produced a clinic-ready prototype and analytical validation on stored samples. The next steps, testing on patients in real settings and a CE marking file, are not yet reported.

1. Four-marker strip, design freezeDeliveredProject report.
2. Reader prototypesDeliveredClinic-ready.
3. Prospective clinical studyNot reportedNext stage.
4. Regulatory submissionQMS in placeISO 13485 aligned.

The Money

Omini's repeated capital increases show it has kept raising money, but not how much. The award was blended finance; whether the EIC equity was among the increases is not stated.

What Cannot Be Checked

Why Europe Should Care

Heart failure is a leading cause of hospitalisation among older people, the EIC report says, and frequent monitoring at home could prevent readmissions. A cheap European multiplex test would fit the shift of care out of hospitals. Omini still has to prove it in patients.

The Verdict

Omini and the EIC have not been asked for comment for this article. It is based entirely on public records and published statements, linked throughout.